View Item 

Show simple item record

Severe Clotting During Extracorporeal Dialysis Procedures

dc.contributor.authorBoyer, Charles J.en_US
dc.contributor.authorSwartz, Richard D.en_US
dc.date.accessioned2010-06-01T20:27:48Z
dc.date.available2010-06-01T20:27:48Z
dc.date.issued1991-04en_US
dc.identifier.citationBoyer, Charles J.; Swartz, Richard D. (1991). "Severe Clotting During Extracorporeal Dialysis Procedures." Seminars in Dialysis 4(2): 69-71. <http://hdl.handle.net/2027.42/73576>en_US
dc.identifier.issn0894-0959en_US
dc.identifier.issn1525-139Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73576
dc.format.extent444814 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights1991 Blackwell Science, Inc.en_US
dc.titleSevere Clotting During Extracorporeal Dialysis Proceduresen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Nephrology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michiganen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73576/1/j.1525-139X.1991.tb00417.x.pdf
dc.identifier.doi10.1111/j.1525-139X.1991.tb00417.xen_US
dc.identifier.sourceSeminars in Dialysisen_US
dc.identifier.citedreferenceSanders PW, Taylor H., Curtis JJ: Hemodialysis without anticoagulation. Am J Kidney Dis 5: 32 – 35, 1985.en_US
dc.identifier.citedreferenceSchwab SJ, Onorato JJ, Sharar LR, Dennis PA: Hemodialysis without anticoagulation: One-year prospective trial in hospitalized patients at risk for bleeding. Am J Med 83: 405 – 410, 1987.en_US
dc.identifier.citedreferenceSwartz RD, Port FK: Preventing hemorrhage in high-risk hemodialysis: Regional versus low-dose heparin. Kidney Int 16: 513 – 518, 1979.en_US
dc.identifier.citedreferenceSwartz R.: Hemorrhage during hemodialysis using controlled heparinization. Nephron 28: 65 – 69, 1981.en_US
dc.identifier.citedreferenceCraddock PR, Fehr J., Brigham K., Kronenberg RS, Jacob HS: Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 296: 769 – 774, 1977.en_US
dc.identifier.citedreferenceHakim RM, Breillatt J., Lazarus JM, Port FK: Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 311: 878 – 882, 1984.en_US
dc.identifier.citedreferenceHakim RM, Schafer AI: Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med 78: 575 – 580, 1985.en_US
dc.identifier.citedreferenceHildebrand U., Quellhorst E.: Influence of various membranes on the coagulation system during dialysis. Contrib Nephrol 46: 92 – 101, 1985.en_US
dc.identifier.citedreferenceMoll S., De Moerloose P., Reber G., Schifffrli J., Leski M.: Comparison of two hemodialysis membranes, polyacrilonitrile and cellulose acetate, on complement and coagulation systems. Int J Artif Organs 13: 273 – 279, 1990.en_US
dc.identifier.citedreferenceNotohamiprodjo M., Andrassy K., Bommer J., Ritz E.: Dialysis membranes and coagulation system. Blood Purif 4: 130 – 141, 1986.en_US
dc.identifier.citedreferenceBerrettini M., Buoncristiani U., Parise P., Ballatori E., Nenci GG: Polyacrilonytrile versus cuprophan membranes for hemodialysis: Evaluation of efficacy and biocompatibility by platelet aggregation studies. Int J Artif Organs 4: 218 – 222, 1981.en_US
dc.identifier.citedreferenceSreharan N., Crow MJ, Salter MCP, Donaldson DR, Rajah SM, Davison AM: Membrane effect on platelet function during hemodialysis: A comparison of cuprophan and polycarbonate. Artif Organs 6: 324 – 327, 1982.en_US
dc.identifier.citedreferenceDocci D., Turci F., Del Vecchio C., Bilancioni R., Cenciotti L., Pretolani E.: Hemodialysis-associated platelet loss: Study of the relative contribution of dialyzer membrane composition and geometry. Int J Artif Organs 7: 337 – 340, 1984.en_US
dc.identifier.citedreferenceKnudsen F., Nielsen AH: Polycarbonate versus cuprophan dialyzers: Effect on platelet function. Blood Purif 2: 173 – 180, 1984.en_US
dc.identifier.citedreferenceVaziri N., Toohey J., Paule P., et al.: Effect of hemodialysis on contact group of coagulation factors, platelets and leukocytes. Am J Med 77: 437 – 441, 1984.en_US
dc.identifier.citedreferenceSchmitt GW, Moake JL, Rudy CK, Vicks SL, Hamburger RJ: Alterations in hemostatic parameters during hemodialysis with dialyzers of different membrane composition and flow design. Am J Med 83: 411 – 418, 1987.en_US
dc.identifier.citedreferenceBjornson J.: Thrombus formation in the artificial kidney. Scand J Urol Nephrol 12: 251 – 257, 1978.en_US
dc.identifier.citedreferenceSchwarzbeck A., Wagner L., Squarr H-U., Strauch M.: Clotting in dialyzers due to low pH of dialysis fluid. Clin Nephrol 7: 125 – 127, 1977.en_US
dc.identifier.citedreferenceBjornson J., Brosstad F.: Platelet and fibrin(ogen) deposition in the artificial kidney: The influence of haematocrit, fibrin monomer and platelet inhibitors. Scand J Urol Nephrol 12: 259 – 264, 1978.en_US
dc.identifier.citedreferenceLivio M., Benigni A., Remuzzi G.: Coagulation abnormalities in uremia. Semin Nephrol 5: 82 – 90, 1985.en_US
dc.identifier.citedreferenceWatson AJ: Adverse effects of therapy for the correction of anemia in hemodialysis patients. Semin Nephrol 9 ( Suppl 1 ): 30 – 34, 1989.en_US
dc.identifier.citedreferenceBick RL: Clinical relevance of antithrombin III. Semin Thromb Hemost 8: 276 – 287, 1982.en_US
dc.identifier.citedreferenceNielsen LE, Bell WR, Borkon AM, Neill CA: Extensive thrombus formation with heparin resistance during extracorporeal circulation. Arch Intern Med 147: 149 – 152, 1987.en_US
dc.identifier.citedreferenceMarciniak E., Gockerman JP: Heparin-induced decrease in circulating antithrombin-III. Lancet 2: 581 – 584, 1977.en_US
dc.identifier.citedreferenceJorgensen KA, Stoffersen E.: Antithrombin III in uremia. Scand J Urol Nephrol 13: 299 – 303, 1979.en_US
dc.identifier.citedreferenceKnudsen F., Dyerberg J.: Platelets and antithrombin III in uremia: The acute effect of hemodialysis. Scand J Clin Lab Invest 45: 341 – 347, 1985.en_US
dc.identifier.citedreferenceToulon P., Jacquot C., Capron L., Frydman M-O., Vignon D., Aiach M.: Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis. Thromb Haemost 57: 263 – 268, 1987.en_US
dc.identifier.citedreferenceBrandt P., Jespersen J., Sorensen LH: Antithrombin-III and platelets in haemodialysis patients. Nephron 28: 103, 1981.en_US
dc.identifier.citedreferenceMatsuo T., Yamada T., Yamanashi T., Kodama K.: Choice of anticoagulant in 9 congenital antithrombin III deficient patients with chronic renal failure undergoing regular hemodialysis. Clin Lab Haematol 11: 213 – 219, 1989.en_US
dc.identifier.citedreferenceAlegre A., Vicente V., Gonzalez R., Alberca I.: Effect of hemodialysis on protein C levels. Nephron 46: 386 – 387, 1987.en_US
dc.identifier.citedreferenceSorensen P., Nielsen A., Knudsen F., Dyerberg J.: Defective protein C in uremia. Blood Purif 5: 29, 1987.en_US
dc.identifier.citedreferenceKnudsen F., Sorensen PJ, Nielsen AH, Dyerberg J.: Functional impairment of protein C activity during haemodialysis—a new mechanism of extracorporeal thrombogenesis. Blood Purif 7: 230 – 232, 1989.en_US
dc.identifier.citedreferenceHenke WJ: Protein C and S response to danacrine in end-stage renal disease. Ann Int Med 106: 910, 1988.en_US
dc.identifier.citedreferenceMehta R., Scott G., Sloand J., Francis C.: Skin necrosis associated with acquired protein C deficiency in patients with chronic renal failure. Am J Med 88: 252, 1990.en_US
dc.identifier.citedreferenceLivio M., Mannucci P., Vigano G., et al.: Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 315: 731, 1986.en_US
dc.identifier.citedreferenceByrnes JJ, Larcada A., Moake JL: Thrombosis following desmopressin for uremic bleeding. Am J Hematol 28: 63 – 65, 1988.en_US
dc.identifier.citedreferenceEl-Shahaway MA, Francis R., Akmel M., Massry SG: Recombinant human erythropoietin shortens bleeding time and corrects abnormal platelet aggregation in hemodialysis patients (Abstract). J Amer Soc Nephrol 1: 397, 1990.en_US
dc.identifier.citedreferenceBabcock RB, Dumper CW, Scharfman WB: Heparin-induced immune thrombocytopenia. N Engl J Med 295: 237 – 241, 1976.en_US
dc.identifier.citedreferenceKing DJ, Kelton JG: Heparin-associated thrombocytopenia. Ann Int Med 100: 535 – 540, 1984.en_US
dc.identifier.citedreferenceSelli C., Amato M., Salvadori M.: Priapism associated with chronic hemodialysis. Dial Transpl 15: 101, 1986.en_US
dc.identifier.citedreferencePusineri F., Bini A., Mussoni L., et al.: Intermittent heparinization does not induce hypercoagulability in haemodialysis patients. J Clin Pathol 33: 631, 1980.en_US
dc.identifier.citedreferenceHabbib M., Haft J.: Heparin resistance induced by intravenous nitroglycerin: A word of caution when both drugs are used concomitantly. Arch Int Med 147: 857, 1987.en_US
dc.identifier.citedreferencePenner JA: Hypercoagulation and thrombosis. Med Clin North Am 64: 743 – 759, 1980.en_US
dc.identifier.citedreferenceKelly A., Hanson J., Henderson L., Harker L.: Prevention of heparinresistant thrombotic occlusion of hollow fiber hemodialyzers by synthetic antithrombin III. J Lab Clin Med 114: 411, 1989.en_US
dc.identifier.citedreferenceZusman RM, Rubin RH, Cato AE, Cocchetto DM, Crow JW, Tolkoff-Rubin N.: Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 304: 934 – 939, 1981.en_US
dc.identifier.citedreferenceSmith MC, Danviriyasup K., Crow JW, Cato AE, Park GD, Hassid A., Dunn MJ: Prostacyclin substitution for heparin in long-term hemodialysis. Am J Med 73: 669 – 678, 1982.en_US
dc.identifier.citedreferenceSwartz R., Flamenbaum W., Dubrow A., et al.: Epoprostenol (PG12; prostacyclin) during high-risk hemodialysis: Preventing further bleeding complications. J Clin Pharmacol 28: 818, 1988.en_US
dc.identifier.citedreferenceWoods H., Ash G., Parsons V., Weston M.: Reduction of dialyzer deposition with sulphinpyrazone. Clin Nephrol 12: 122, 1979.en_US
dc.identifier.citedreferenceMaurin N., Ballmann M.: Prevention of coagulation during hemodialysis by a combination of the stable prostacyclin analogue CG 4203 and low-dose heparin. Clin Nephrol 30: 35, 1988.en_US
dc.identifier.citedreferenceHenny C., Ten Cate H., Surachno S., et al.: The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis. Thromb Haemost 54: 460, 1985.en_US
dc.identifier.citedreferencePinnick R., Weigmann T., Diderich D.: Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 308: 258, 1983.en_US
dc.identifier.citedreferenceMehta RL, McDonald BR, Aguilar MM, Ward DM: Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 38: 976 – 981, 1990.en_US
dc.identifier.citedreferenceToomasian JM, Helmer GA, Zeme MI, Oltean JN, Oran AD, Bartlett RH: Control of thrombosis in extracorporeal circulation: Variations of anticoagulation. Trans Am Soc Artif Organs 29: 206 – 209, 1983.en_US
dc.identifier.citedreferenceLanger R., Linhardt RJ, Hoffberg S., Larsen AK, Cooney CL, Tapper D., Klein M.: An enzymatic system for removing heparin in extracorporeal therapy. Science 217: 261 – 263, 1982.en_US
dc.identifier.citedreferenceTeng C-LC, Kim J-S., Port FK, Wakefield TW, Till GO, Yang VC: A protamine filter for extracorporeal blood heparin removal. Trans Am Soc Artif Organs 34: 743 – 746, 1988.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1525-139X.1991.tb00417.x.pdf
Size:
434.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.